ND

Treatment tested

• Levetiracetam

  Synaptic vesicle glycoprotein 2A modulator|Voltage-gated N-type calcium channel alpha-1B subunit blocker

Inclusion: 1) male and female aged &#8805; 18 years old < 65 years old; 2) Diagnosis of stable multiple sclerosis (according to Poser criteria), without relapses or a worsening major than 1 point at the EDSS (Expanded Disability Status Scale) in the last 3 months before 3) EDSS < than 7.5 at inclusion 4) Presence of kinetic-intention tremor (tremor will be assessed in 3 states of the arm: rest, posture, movement during a finger-noise-finger test) 5) SCRIPPS scale for sensory and motor system &#8805; than 3 6) Ashworth scale < than 2 7) written informed consent Exclusion: 1) prior exposure to Levetiracetam 2) hepatopathy acute and chronic; 3) renal and pancreatic insufficiency; 4) female subjects who are pregnant or lactating; sexually active women with childbearing potential who are not using a medically accepted birth control method. 5) patients with contraindication to levetiracetam and/or to pyrrolidine derivates use; 6) cerebrovascular disease; 7) subjects with a malignancy or with a history of malignancy within the past five years;

The primary objective of this study is to evaluate the efficacy of Levetiracetam on cerebellar symptoms (through the 9 hole-peg test) in patients affected by Multiple Sclerosis.